Published in final edited form as:

Int J Gynecol Pathol. 2015 November ; 34(6): 551–563. doi:10.1097/PGP.0000000000000206.

Secondary involvement of the adnexa and uterine corpus by carcinomas of the uterine cervix: a detailed morphologic description

Carolina Reyes, M.D.,

Assistant Professor Surgical Pathology, Director Gynecologic Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA

Rajmohan Murali, MBBS, MD, FRCPA, and

Department of Pathology, Memorial Sloan Kettering Cancer Center, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Kay J. Park, MD

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

INTRODUCTION

Carcinomas of the uterine cervix affect 500,000 women worldwide, half of whom will die of the disease every year (CDC fact sheet). Squamous cell carcinoma (SCC) is the most common histologic subtype and adenocarcinoma (AC) comprises approximately 25% of cases [1]. The incidence of ovarian metastases ranges from 2–28.6% for cervical AC and 0–17.4% for SCC, depending on stage of disease [2–6]. The histologic appearance of cervical adenocarcinoma involving the ovaries has been well described, highlighting the propensity for these metastases to simulate primary ovarian surface epithelial neoplasms including borderline tumors and well-differentiated carcinomas [7, 8]. The pattern of ovarian involvement by cervical SCC is not well described, nor is the involvement of the uterine corpus and fallopian tubes by cervical carcinomas. In this study, we performed a detailed morphologic analysis of endocervical AC and cervical SCC with secondary involvement of adnexa (ovaries, fallopian tubes) and/or uterine corpus.

MATERIALS AND METHODS

The institutional database at Memorial Sloan Kettering Cancer Center (MSK) was searched for patients diagnosed with cervical cancer with secondary involvement of the adnexa and/or uterine corpus between 1997 and 2012. Squamous cell carcinoma and human papillomavirus (HPV)-associated usual cervical ACs were included; other histologic variants such as clear cell, mesonephric and gastric type were excluded. Pathologic reports and all available slides of the primary tumors and the secondarily involved sites were reviewed. The following clinico-pathologic features were recorded: clinically visible tumor in cervix, tumor size,

Corresponding author: Kay J. Park, MD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave. New York, NY 10065, (212) 639-2719 (p), (212) 639-2631 (f), parkk@mskcc.org.

Funding source: none

presence of lymphovascular invasion (LVI) and corpus and/or adnexal involvement. The following histologic patterns of involvement at each site were also recorded: colonization of pre-existing epithelium, nodular vs. infiltrating, laterality, presence of surface nodules and ovarian size. The following features of ovarian involvement by AC were noted: papillary/villoglandular growth with or without glandular confluence and destructive stromal invasion. Expansile growth was defined as the presence of confluent glandular epithelium with cribriform areas but no desmoplastic stromal invasion. Destructive stromal invasion was categorized as invasive.

RESULTS

Clinicopathologic features of the cases are summarized in Table 1. Of 538 patients with cervical carcinoma who underwent surgery, there was secondary involvement of the adnexa and/or corpus in 20 patients meeting our criteria. The patients ranged in age from 32 to 73 years (median=45 years), and the cervical carcinomas were invasive and in-situ/high grade squamous intraepithelial lesion (HSIL/CIN3) in 18 (90%) and 2 (10%) patients, respectively. The majority of patients with invasive carcinoma (17/18, 94%) presented with clinically visible lesions and advanced stage disease with metastases to the peritoneum (3/18) or lymph nodes (3/18).

The number of slides reviewed in each case ranged from 7 to 39 with a mean of 22. The histologic subtypes of the cervical tumors were: SCC (n=8); AC (n=9); HSIL/CIN3 with no invasive carcinoma (n=2); and adenosquamous carcinoma (n=1). The adenosquamous carcinoma (patient 13) was composed mostly of glands with a minor squamous component and was therefore grouped with the adenocarcinomas for the purposes of this study. One patient with AC (patient 16) was found to have suspicious adnexal masses and positive lymph nodes on imaging. Bilateral adnexa and lymph nodes were removed for diagnostic purposes and no hysterectomy was performed due to advanced stage disease.

One patient (patient 1) with cervical HSIL/CIN3 but no invasive carcinoma on cone biopsy showed diffusely metastatic SCC including extensive involvement of the ovary. She was human immunodeficiency virus (HIV)-positive and was found to have a focus in the cervix with an exuberant lymphocytic reaction in the stroma suggestive of regressed invasive carcinoma. The second patient with HSIL/CIN3 was undergoing a trachelectomy due to repeated positive margins on multiple cone biopsies (patient 2). The trachelectomy was converted to hysterectomy without salpingo-oophorectomy for positive endocervical margin and tumor in the endometrial curettage at the time of surgery.

Of the 8 invasive SCC of the cervix, 7 involved the uterine corpus (one case did not have a hysterectomy and therefore corpus involvement could not be evaluated). One of the HSIL cases involved the ovary and fallopian tube but not the corpus while the other HSIL involved the endometrium only (adnexa not removed and therefore not evaluated). Four of the 7 SCC with corpus involvement also had adnexal involvement (2 tube only, 2 tubes and ovaries), while the other 3 showed no adnexal metastases. One case with metastatic SCC in bilateral ovaries and left fallopian tube did not have hysterectomy due to high stage disease at time of surgery, therefore the corpus was not assessed (patient 6).

Of the 10 invasive AC, 8 involved the uterine corpus (one case did not have a hysterectomy and therefore corpus involvement could not be evaluated). Six of the 8 cases with corpus involvement also had adnexal involvement (3 tube only, 3 tubes and ovaries), while the other 2 showed no adnexal metastases.

Lymphovascular invasion was identified in 7/8 invasive SCC and 6/10 AC. Two cases involved the adnexa only (1 HSIL, 1 AC), 6 the corpus only (1 HSIL, 3 SCC, 2 AC) and 10 involved both sites (4 SCC, 6 AC). When present in the fallopian tube, tumor was almost always present in the ovary or endometrium. Only one case (AC) had involvement of the fallopian tube without involvement of ovary or corpus (patient 20).

Interestingly, 4 of the 10 patients with adenocarcinoma were originally diagnosed with endometrial endometrioid adenocarcinoma at outside hospitals (patients 12, 13, 14, 18). Three had diffuse infiltration of the endometrium and myometrium while one (patient 18) had mucosal colonization of the endometrium spreading in a lateral “carpet-like” pattern. This patient’s tumor also had a papillary/villoglandular growth pattern with abundant eosinophilic cytoplasm, truly mimicking an endometrial endometrioid adenocarcinoma. Two of the cases showed endocervical adenocarcinoma in-situ in the cervix.

Immunohistochemical studies had been performed on all four cases during routine work-up and all were found to be diffusely positive for p16, at least focally positive for monoclonal CEA, negative for vimentin and no more than focally positive for ER or PR – consistent with endocervical adenocarcinoma. Of note, patient 13 was originally diagnosed with endometrial endometrioid adenocarcinoma and presented to our institution with a mesenteric cyst 7 years post hysterectomy. Immunohistochemistry performed on that cyst was consistent with endocervical adenocarcinoma, and, in addition, the glands lining the cysts were positive for high-risk human papillomavirus by HPV ISH (Ventana INFORM® HPV III). Comparison of the original hysterectomy to the cyst showed that they were the same tumor.

Corpus involvement by Adenocarcinoma

Corpus involvement was characterized by tumor colonizing endometrial mucosa and in some cases with extension into the myometrium. Of the 10 AC, 8 involved the corpus, 6 of which also involved the adnexa. AC involved endometrial mucosa in all cases and 5 also involved the myometrium. The following patterns of endometrial mucosal involvement were noted: villoglandular and cribriform glands replacing the vast majority of existing endometrial glands such that it resembled primary endometrioid adenocarcinoma of the endometrium (Fig. 1); endocervical adenocarcinoma colonizing endometrium with underlying normal endometrial glands and stroma such that it resembled complex atypical hyperplasia (Fig. 2); involvement of adenomyosis by endocervical AC maintaining a lobulated outline (Fig. 3). The myometrial involvement was usually extensive with deep invasion into the wall associated with large cervical masses.

Corpus involvement by Squamous cell carcinoma/HSIL

SCC involved the uterine corpus in all 7 cases where the corpus was assessed, 4 of which had concurrent adnexal involvement. In all but 2 cases, SCC involved both the endometrium

and myometrium and when the myometrium was involved, it was always in a diffusely infiltrative pattern with deep invasion and obliteration of the endometrial mucosa. The primary tumors were large (> 4.0 cm) or deeply invasive into the cervical wall with direct extension into the corpus. Tumor invaded endometrial stroma, sometimes surrounding individual native endometrial glands (Fig. 4A) as well as colonizing them (Fig. 4B, 4C). These appeared to be a result of direct extension from the cervix and in one case, from tumor invading the deep myometrium with upward migration toward the endometrial lining. Two cases showed only colonization of endometrium with involvement of glands in a “carpet-like” fashion, similar to that seen in adenocarcinoma (Fig. 5). The one HSIL involving the corpus showed focal gland colonization in the endometrium, similar to the common pattern of HSIL colonizing native endocervical glands.

Adnexal involvement by Adenocarcinoma

Four of 10 endocervical AC had ovarian metastases, synchronous in all cases. The ovarian tumors ranged in size from 2.6 cm to 16.2 cm, 2 bilateral, 2 unilateral, with one case showing bilateral ovaries greater than 10 cm (all other involved ovaries were no greater than 8 cm). Three cases had visible surface nodules and the remaining one had a smooth ovarian surface. All showed a mostly solid cut surface. The ovarian tumors showed confluent papillary and cribriform glands with expansile growth. Cribriform structures were characterized by rigid and round lumens (Fig. 6). In one case (patient 19) broad based papillae with hierarchical branching was also noted, very closely recapitulating the typical architecture of ovarian borderline tumors (Fig. 7A). Focal areas even resembled micropapillary serous borderline tumor with elongated tufts of tumor cells unsupported by fibrovascular cores (Fig. 7B). Occasionally, the epithelium lining the broad papillae became attenuated with minimal atypia and apocrine cytoplasm, truly resembling a cystadenofibroma (Fig. 7C). Immunohistochemistry performed on both ovaries showed that the tumor was diffusely and strongly positive for p16 and monoclonal CEA, negative for vimentin and PR with weak patchy ER reactivity. High risk human papillomavirus was detected by HPV ISH as well (Ventana INFORM® HPV III). Careful examination of the histology revealed areas with more columnar epithelium with prominent mitoses and apoptotic bodies, though these features were not prominent. One case had only a small nodule of neoplastic glands in mucin pools on the ovarian serosa (Fig. 8). In all of the cases the tumors showed “endometrioid” morphology displaying tall columnar cells with elongated nuclei and only focal mucinous differentiation. High power examination revealed characteristic features of endocervical AC - hyperchromatic elongated nuclei, moderate atypia with numerous apical mitoses and apoptotic bodies (Fig. 9).

Fallopian tube metastasis by endocervical AC was seen in 8 of the 10 cases and the lesions were all microscopic measuring between 0.1 cm and 0.4 cm except for one case (patient 17) who presented with vaginal discharge and large adnexal masses. She was thought to have a fallopian tube primary carcinoma and showed papillary, exophytic masses in the paratubal soft tissue. This was the only case of bilateral tubal involvement; all others were unilateral and either microscopically colonized pre-existing fallopian tube epithelium simulating serous tubal intraepithelial carcinoma (STIC) on low power (6 cases) (Fig. 10A, 10B) or had small serosal implants (1 case). Some showed papillary tufting and slit-like spaces more

typical of high-grade serous carcinomas with high nuclear grade (Fig. 10C). The lesions were multifocal and ranged from flat (Fig. 10D) to cribriform (Fig. 10E) to papillary (Fig. 10F). Focal stromal invasion was occasionally seen (Fig. 10G). Closer inspection revealed intracytoplasmic goblet-like mucin in some of the cells and overall the tumors resembled the cervical tumor (Fig. 10H).

Adnexal involvement by Squamous cell carcinoma/HSIL

Three of 8 patients with cervical SCC had ovarian involvement, while one patient with cervical HSIL showed invasive SCC in one ovary. Ovarian and/or fallopian tube involvement was evident at the time of diagnosis in all but one case (patient 10) and lymphovascular invasion in the periadnexal soft tissue was often present. Ovarian involvement was unilateral (3) and bilateral (1) with ovarian sizes ranging from 2 cm to 7.5 cm. One case showed tumor in the left ovary and the right periadnexal soft tissue. Two of the four cases had grossly visible ovarian surface nodules while the other 2 had smooth surfaces without evident tumor. All of the cases revealed nodules of SCC replacing normal ovarian parenchyma with stromal invasion (Fig. 11).

The fallopian tubes were involved in 6 SCC, all unilateral. Lesions were small and measured less than 1 cm in three cases. The other three cases showed grossly enlarged fallopian tubes. In one case, the tumor colonized the mucosa of a cystically dilated fallopian tube, resulting in a 9 cm cystic mass (patient 3). There was no stromal invasion and the cystically dilated tube had the appearance of an in-situ SCC (Fig. 12A). The interesting part regarding this case is that the primary cervical lesion was predominantly HSIL with only focal stromal invasion, however, had extensive “carpeting” of the endometrium by SCC without myometrial invasion (Fig. 12B). The ipsilateral ovary was not involved except in the form of lymphovascular invasion in the periadnexal vessels. A second case had an intraluminal tubal mass with replacement of the tubal mucosa (patient 6) (Fig. 13). The third was one case of HSIL in an HIV positive patient who presented with invasive SCC in the ovary and fallopian tube (Fig 14A). There was an area of inflammation associated with her cervical HSIL that suggested possible regression of an invasive tumor (Fig. 14B). There was no other obvious source of invasive SCC. Two cases had nodules of squamous cell carcinoma surrounding the fallopian tube. One case showed keratin granulomas on the tubal serosa with a minute focus of SCC colonizing the tubal epithelium beneath the granuloma (Fig. 15A). This focus was highlighted by diffuse strong p16 reactivity (Fig. 15B).

DISCUSSION

Although there are reports describing the morphologic features of cervical AC and SCC metastatic to ovaries, little is written about involvement of fallopian tubes and direct extension to the uterine corpus. The 20 cases presented in this study illustrate the patterns of ovarian and/or fallopian tube and endometrial involvement by cervical SCC and AC. Cervical SCC and AC infrequently metastasize to the adnexa [2, 3] and the reported cases in the literature mainly describe ovarian involvement [5–8].

Endocervical AC metastatic to the ovary tends to simulate primary ovarian surface epithelial neoplasms [7, 8] frequently exhibit mucinous and endometrioid differentiation, which often

in this study, but when in doubt one can perform immunohistochemistry for p53 and HPV in-situ hybridization (ISH) when this differential diagnosis arises: endocervical AC are characterized by positive HPV ISH and no p53 over-expression, whereas STIC exhibits p53 overexpression or null pattern and negative HPV ISH. It should be noted that there are several commercially available HPV ISH tests, some of which are less sensitive than others, in particular for adenocarcinoma [22, 23]. Immunohistochemistry for p16 in this setting is not helpful since both high grade serous tumors and HPV-associated cervical cancers are typically diffusely positive for this marker.

In all cases of endocervical AC secondarily involving the endometrium, the tumor colonized or obliterated normal endometrial glands. Endocervical AC frequently demonstrate “endometrioid” morphology and if there is dominant uterine corpus involvement by endocervical adenocarcinoma it can lead to misclassification as primary endometrial adenocarcinoma with cervical extension or even complex atypical hyperplasia if present on an endometrial biopsy [24]. In our cases, this scenario was observed in 4 cases where the patient was initially diagnosed as having an endometrial primary.

It is rare to encounter metastatic cervical SCC or AC in the adnexa. Most cases of cervical SCC secondarily involving ovaries in this study had a nodular appearance at low power magnification. Although only 1 of the 4 cases had bilateral ovarian tumors, they all showed areas of destructive stromal invasion suggestive of a metastatic process and 3 exhibited ovarian surface nodules. Fallopian tube involvement by SCC was seen in the form of carcinoma replacing and colonizing fallopian tube epithelium and also in the form of nodules of SCC surrounding the tube. Most of our cervical SCC were deeply invasive with a visible lesion. We had one case of adnexal/endometrial involvement by SCC limited to superficial cervical invasion, which has been described by others [25,26]. One patient had HSIL only in the cervix with invasive SCC in the ovary and fallopian tube presenting as a large pelvic mass. There is one other report of ovarian SCC occurring in a setting of microinvasive SCC 8 years after the original diagnosis [27].

As previously reported, the vast majority of cases of adnexal involvement occurred in the setting of advanced stage cervical carcinoma with extrauterine involvement or large bulky primary tumors. However, there were cases of early stage disease and even cases of non-invasive squamous carcinoma that extended into the uterine corpus and adnexa. Specifically, the “carpeting” growth pattern of tumor spreading superficially and laterally along the endometrium was seen in both squamous and adenocarcinomas with tumor involving adnexa without obvious myometrial or lymphovascular invasion. This phenomenon should be taken into consideration when contemplating ovary and fallopian tube sparing hysterectomies in patients with minimal or no invasive disease. One patient (patient 1) with only cervical HSIL showed diffusely metastatic SCC including extensive involvement of the ovary. She was HIV-positive and was found to have a focus in the cervix with an exuberant lymphocytic reaction in the stroma as is typically seen in regressing melanomas. This may have represented regressed invasive carcinoma, though there was no definitive evidence to support this.

In summary, we have presented a relatively large study of cervical carcinomas that secondarily involve the corpus, ovaries and fallopian tubes. There is overlap between the histological appearances of these tumors and primary carcinomas arising at these sites, and erroneous assignment of the primary tumor site may lead to inappropriate and potentially harmful treatment. Careful morphologic evaluation, allied with clinico-pathologic correlation and the judicious use of ancillary tests such as immunohistochemistry and ISH, will help avoid diagnostic pitfalls and allow accurate diagnosis.

References

1. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. *Gynecol Oncol.* 2000; 78:97–105. [PubMed: 10926787]
2. Toki N, Tsukamoto N, Kaku T, et al. Microscopic ovarian metastasis of the uterine cervical cancer. *Gynecol Oncol.* 1991; 41:46–51. [PubMed: 2026359]
3. Sutton GP, Bundy BN, Delgado G, et al. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. *Am J Obstet Gynecol.* 1992; 166:50–53. [PubMed: 1733218]
4. Tabata M, Ichinoe K, Sakuragi N, et al. Incidence of ovarian metastasis in patients with cancer of the uterine cervix. *Gynecol Oncol.* 1987; 28:255–261. [PubMed: 3678976]
5. Nakanishi T, Wakai K, Ishikawa H, et al. A comparison of ovarian metastasis between squamous cell carcinoma and adenocarcinoma of the uterine cervix. *Gynecol Oncol.* 2001; 82:504–509. [PubMed: 11520147]
6. Shimada M, Kigawa J, Nishimura R, et al. Ovarian metastasis in carcinoma of the uterine cervix. *Gynecol Oncol.* 2006; 101:234–237. [PubMed: 16300819]
7. Elishaev E, Gilks CB, Miller D, et al. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. *Am J Surg Pathol.* 2005; 29:281–294. [PubMed: 15725796]
8. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. *Am J Surg Pathol.* 2008; 32:1835–1853. [PubMed: 18813124]
9. Young RH, Scully RE. Invasive adenocarcinoma and related tumors of the uterine cervix. *Semin Diagn Pathol.* 1990; 7:205–227. [PubMed: 2218147]
10. Zaino RJ. Glandular lesions of the uterine cervix. *Mod Pathol.* 2000; 13:261–274. [PubMed: 10757337]
11. Kaminski PF, Norris HJ. Coexistence of ovarian neoplasms and endocervical adenocarcinoma. *Obstet Gynecol.* 1984; 64:553–556. [PubMed: 6483301]
12. LiVolsi VA, Merino MJ, Schwartz PE. Coexistent endocervical adenocarcinoma and mucinous adenocarcinoma of ovary: a clinicopathologic study of four cases. *Int J Gynecol Pathol.* 1983; 1:391–402. [PubMed: 6309685]
13. Yada-Hashimoto N, Yamamoto T, Kamiura S, et al. Metastatic ovarian tumors: a review of 64 cases. *Gynecol Oncol.* 2003; 89:314–317. [PubMed: 12713997]
14. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. *Am J Surg Pathol.* 2003; 27:281–292. [PubMed: 12604884]
15. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. *Am J Surg Pathol.* 1999; 23:617–635. [PubMed: 10366144]

16. Yemelyanova AV, Vang R, Judson K, et al. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. *Am J Surg Pathol*. 2008; 32:128–138. [PubMed: 18162780]
17. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. *Am J Surg Pathol*. 2003; 27:985–993. [PubMed: 12826891]
18. Daya D, Nazerali L, Frank GL. Metastatic ovarian carcinoma of large intestinal origin simulating primary ovarian carcinoma. A clinicopathologic study of 25 cases. *Am J Clin Pathol*. 1992; 97:751–758. [PubMed: 1595595]
19. Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. *Am J Surg Pathol*. 1997; 21:1144–1155. [PubMed: 9331286]
20. Ronnett BM, Kurman RJ, Zahn CM, et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. *Hum Pathol*. 1995; 26:509–524. [PubMed: 7750935]
21. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. *Histopathology*. 2002; 41:185–207. [PubMed: 12207781]
22. Kong CS, Balzer BL, Troxell ML, et al. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. *Am J Surg Pathol*. 2007; 31:33–43. [PubMed: 17197917]
23. Sheng Z, Minato H, Sasagawa T, et al. Detection of high-risk human papillomavirus subtypes in cervical glandular neoplasia by in situ hybridization. *Int J Clin Exp Pathol*. 2013; 6:2168–77. [PubMed: 24133595]
24. Yemelyanova A, Vang R, Seidman JD, et al. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. *Am J Surg Pathol*. 2009; 33:914–924. [PubMed: 19295407]
25. Gungor T, Altinkaya SO, Ozat M, et al. Unusual form of superficial spreading squamous cell carcinoma of cervix involving the endometrium, bilateral tubes and ovaries: a case report with literature review. *Arch Gynecol Obstet*. 2011; 283:323–327. [PubMed: 20852876]
26. Pins MR, Young RH, Crum CP, et al. Cervical squamous cell carcinoma in situ with intraepithelial extension to the upper genital tract and invasion of tubes and ovaries: report of a case with human papilloma virus analysis. *Int J Gynecol Pathol*. 1997; 16:272–278. [PubMed: 9421094]
27. Hidaka T, Nakashima A, Hasegawa T, et al. Ovarian squamous cell carcinoma which metastasized 8 years after cervical conization for early microinvasive cervical cancer: a case report. *Jpn J Clin Oncol*. 2011; 41:807–810. [PubMed: 21467082]

Figure 1. Endocervical adenocarcinoma replacing endometrium resembling primary endometrioid adenocarcinoma (40x).

Figure 2. Endocervical adenocarcinoma colonizing endometrial glands resembling complex atypical hyperplasia; notice benign endometrial glands of basalis beneath neoplastic glands (40x).

Figure 3. Endocervical adenocarcinoma involving adenomyosis in myometrium with retained lobular configuration of glands; adenocarcinoma also colonizes endometrium in top left corner (20x).

Figure 4. Squamous cell carcinoma involving endometrium; **(A)** invading endometrial stroma and surrounding native endometrial glands (100x); **(B)** SCC completely replacing (40x), and **(C)** colonizing (100x) endometrial glands.

Figure 5.
Carpet-like involvement of endometrium by SCC (40x).

Figure 6. Characteristic features of endocervical adenocarcinoma with confluent papillary glands and cribriform structures with rigid round lumens (100x).

Figure 7.

Endocervical adenocarcinoma involving ovary and mimicking borderline tumor. (A) Broad based papillae with hierarchical branching and epithelial tufting (40x); (B) Elongate tufts of tumor cells unsupported by fibrovascular cores, resembling micropapillary borderline tumor (100x); (C) flat epithelial lining of tumor cells resembling cystadenofibroma; notice mitotic figure and intracytoplasmic mucin in upper right corner (100x).

Figure 8.
Metastatic endocervical adenocarcinoma with extravasated mucin on ovarian surface (40x).

Figure 9. Mucin depleted “endometrioid” appearance of metastatic endocervical adenocarcinoma with numerous luminal mitotic figures and abundant apoptotic bodies (400x).

Figure 10.

Endocervical adenocarcinoma metastatic to fallopian tubes. **(A, B)** 40x Mucosal colonization by AC resembling STIC; **(C)** 100x Papillary tufting and slit-like spaces with high nuclear grade mimicking serous carcinoma; **(D)** 400x Flat; **(E)** 40x Cribriform; and **(F)** 100x Papillary appearance of endocervical AC in fallopian tube mucosa; **(G)** 100x focal stromal invasion of fallopian tube wall; **(H)** 400x Intracytoplasmic mucin goblets of endocervical AC.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 11.
Nodule of metastatic SCC involving ovarian parenchyma (20x).

Figure 12.

(A) 40x Cystic dilatation of fallopian tube colonized by SCC in a patient with predominantly HSIL and extensive (B) 100x carpet-like growth into endometrium with replacement of endometrial glands.

Figure 13.
Intraluminal mass of metastatic SCC involving fallopian tube and replacing tubal mucosa (40x).

Figure 14.
(A) 20x Metastatic SCC with invasion into fallopian tube wall in an HIV positive patient with HSIL and area of inflammation in cervix; (B) 40x possibly representing regressed invasive tumor.

Figure 15.
(A) 400x Metastatic SCC with focal mucosal colonization of mucosa and associated keratin granuloma highlighted by diffuse strong (B) 400x CINtec® p16 (Ventana, Tucson, AZ, USA).

Clinicopathologic Features of Cervical Carcinomas with Ovarian, Fallopian tube and/or Endometrial Involvement

Table 1

Pt	Age (yr)	Tumor Type	Stage at diagnosis	LVI	Corpus Involvement		Ovarian Involvement				FT Involvement	
						Microscopic	Laterality	Ovary Size (cm)	Gross	Microscopic	Laterality	Microscopic
1	37	HSIL *	IVB *	0	0	--	Right	7.5	Smooth surface	Destructive and nodular invasion	Left	Invasion of tubal wall
2	44	HSIL ^	0	0	1	Colonization of glands	NA	NA	NA	NA	NA	NA
3	60	SCC	IB1	1	1	Colonization of glands; "carpet-like"	--	--	--	--	Left	Cystically dilated tube with mucosal colonization
4	40	SCC	IIIB	1	1	Diffuse infiltration of endomyometrium	Right	7	Surface nodule, small	Parenchymal nodules	Right	Serosal and stromal invasion
5	60	SCC	IB2	0	1	Diffuse infiltration of endomyometrium	--	--	--	--	--	--
6	60	SCC	IVB	1	NA #	NA	BL	2.2, 2.5	Surface nodules, solid	Parenchymal nodules	Right	Mass in lumen
7	44	SCC	IB2	1	1	Diffuse infiltration of endomyometrium	--	--	--	--	--	--
8	42	SCC	IIA2	1	1	Diffuse infiltration of endomyometrium	Left	2.0	Smooth surface	Parenchymal nodules	Right	Serosal and stromal invasion
9	55	SCC	IIB	1	1	Colonization of glands; "carpet-like"	--	--	--	--	--	--
10	46	SCC	IB2	1	1	Diffuse infiltration of endomyometrium with papillary growth	--	--	--	--	Right	0.3 cm focus of mucosal colonization, keratin granulomas
11	60	AC	IIA2	1	1	Diffuse infiltration of endomyometrium	--	--	--	--	Right	Mucosal colonization
12	49	AC	IIA2	1	1	Diffuse infiltration of endomyometrium with invasion into leiomyoma	Left	2.6	Mass on surface, solid	Expansile and invasive	Right	Mucosal colonization with Intraluminal lesion
13	62	AC	IB1	1	1	Diffuse infiltration of endomyometrium	--	--	--	--	--	--
14	43	AC	IB2	1	1	Diffuse infiltration of endomyometrium	--	--	--	--	--	--
15	45	AC	IB1	1	1	Colonization of endometrium including adenomyosis; "carpet-like"	--	--	--	--	Left	Mucosal colonization

Pt	Age (yr)	Tumor Type	Stage at diagnosis	LVI	Corpus Involvement		Ovarian Involvement				FT Involvement	
						Microscopic	Laterality	Ovary Size (cm)	Gross	Microscopic	Laterality	Microscopic
16	40	AC	IIB	0	NA @	NA	Right	4.0	Smooth	Small surface nodule with glands in mucin pools	Right	Mucosal colonization
17	48	AC	IIB	1	1	Colonization of endometrium with deep myometrial invasion	--	--	--	--	BL	Papillary, exophytic masses in paratubal soft tissue
18	44	AC	IIA2	0	1	Colonization of endometrium, papillary, villoglandular, eosinophilic; "carpet-like"	BL	8.0, 2.8	Surface nodules, solid	Surface nodules, papillary, expansile	Right	Mucosal colonization
19	44	AC	IVB	0	1	Colonization of endometrium, exophytic papillary; "carpet-like"	BL	15, 16.2	Nodular fungating tumor on surface	Expansile and infiltrative	Left	Small serosal implants
20	48	AC	IB1	0	0	--	--	--	--	--	Left	Mucosal colonization

1: Present; 0: Absent; NA: Not assessed; HSIL: High grade squamous intraepithelial lesion; AC: Adenocarcinoma; SCC: squamous cell carcinoma; BL: Bilateral; FT: Fallopian Tube

* HIV positive patient with history of HSIL, presented with widely metastatic SCC

^ Completion hysterectomy at time of trachelectomy for HSIL at endocervical margin

No hysterectomy performed, adnexa removed at time of exploratory laparotomy

@ Adnexa removed for diagnostic purposes, clinically high stage